Home > News > Industry > Pharma News > ChrysCapital, Capital...

ChrysCapital, Capital Group sell 7.6 percent stake in Mankind Pharma for Rs 5589 crore

By - Ruchika Sharma
Published On 2023-12-13 09:00 GMT   |   Update On 2023-12-13 12:17 GMT

New Delhi: ChrysCapital and Capital Group has divested a total of 7.6 per cent stake in pharmaceutical company Mankind Pharma for Rs 5,589 crore through open market transactions. Following the stake sale, shares of Mankind Pharma Ltd fell 3.65 per cent to close at Rs 1,850 apiece on the NSE. The stock declined 3.61 per cent to settle at Rs 1,849.45 on BSE.Beige Ltd, an affiliate of private...

Login or Register to read the full article
Register Now

New Delhi: ChrysCapital and Capital Group has divested a total of 7.6 per cent stake in pharmaceutical company Mankind Pharma for Rs 5,589 crore through open market transactions. Following the stake sale, shares of Mankind Pharma Ltd fell 3.65 per cent to close at Rs 1,850 apiece on the NSE. The stock declined 3.61 per cent to settle at Rs 1,849.45 on BSE.

Beige Ltd, an affiliate of private equity firm ChrysCapital, pared 4.47 per cent stake while Cairnhill CIPEF and Hema CIPEF (I) Ltd, (affiliates of Capital Group) offloaded a 3.14 per cent stake in Mankind Pharma.
As per the bulk deal data, Beige Ltd sold a total of 1,79,10,132 shares of Mankind Pharma on BSE and NSE, while Cairnhill CIPEF and Hema CIPEF (I) Ltd offloaded 1,25,88,400 shares of the company on NSE.
The shares were disposed of in the price range of Rs 1,832.30-1,832.80 apiece, taking the combined transaction value to Rs 5,588.71 crore.
After the transaction, Beige Ltd's shareholding declined to 2.99 per cent from 7.46 per cent, while Hema CIPEF (I) Ltd's stakeholding reduced to 2.23 per cent from 3.63 per cent.
Also, Cairnhill CIPEF sold its entire 1.74 per cent stake and exited the firm.
On the BSE, Kotak Funds India Midcap Fund acquired 20.29 lakh shares of Mankind Pharma at an average price of Rs 1,832.30 apiece, taking the deal size to Rs 372 crore.
Incorporated in 1991, Mankind Pharma develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
Mankind produces branded generic drugs sold throughout India, with a uniquely deep reach in rural and semi-urban markets.
In May this year, Mankind Pharma's IPO had a stellar debut on the bourses. The company's Rs 4,326-crore IPO was one of the biggest by a domestic pharmaceutical player since Gland Pharma made its market debut with a Rs 6,479.5-crore IPO in 2020.
Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

CDSCO Panel grants Zydus Lifscience Proposal For Additional Indication of Trivalent Influenza vaccine in 6 months to 17 years age
Dr Reddy's Labs expects strong product pipeline in North America for FY25
Zydus Lifesciences bags USFDA nod for Dapsone Gel for acne treatment
USFDA approves Alembic Pharma five products in over a month
Lupin ropes in Jeffrey Kindler, Alfonso Zulueta as Independent Directors
Cipla gets 1 inspectional observation from USFDA for Maha facility
USFDA Advisory Committee to convene meeting to discuss on Eli Lilly Alzheimer's drug donanemab
Lupin net profit surges 52 percent at Rs 359 crore in Q4